Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Operating Expenses: 2009-2025

Historic Operating Expenses for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $23.6 million.

  • Gyre Therapeutics' Operating Expenses rose 11.22% to $23.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.2 million, marking a year-over-year decrease of 47.43%. This contributed to the annual value of $89.6 million for FY2024, which is 50.41% down from last year.
  • Per Gyre Therapeutics' latest filing, its Operating Expenses stood at $23.6 million for Q3 2025, which was down 3.91% from $24.6 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Operating Expenses high stood at $124.0 million for Q4 2022, and its period low was -$51.5 million during Q2 2022.
  • Over the past 3 years, Gyre Therapeutics' median Operating Expenses value was $22.0 million (recorded in 2024), while the average stood at $30.8 million.
  • Examining YoY changes over the last 5 years, Gyre Therapeutics' Operating Expenses showed a top increase of 444.79% in 2022 and a maximum decrease of 344.84% in 2022.
  • Gyre Therapeutics' Operating Expenses (Quarterly) stood at $22.8 million in 2021, then spiked by 444.79% to $124.0 million in 2022, then declined by 4.18% to $118.8 million in 2023, then plummeted by 77.09% to $27.2 million in 2024, then rose by 11.22% to $23.6 million in 2025.
  • Its Operating Expenses stands at $23.6 million for Q3 2025, versus $24.6 million for Q2 2025 and $19.8 million for Q1 2025.